Market Place
Sourcing Support
Annual General Meeting Resolutions
24 Apr 2026 //
GLOBENEWSWIRE
Grant of Warrants Approved
14 Apr 2026 //
GLOBENEWSWIRE
Major Shareholder Announcement
13 Apr 2026 //
GLOBENEWSWIRE
Bioporto Divests Antibody Business to Janel Life
08 Apr 2026 //
GLOBENEWSWIRE
BioPorto Files FDA Pre-Sub for Adult Urine NGAL Program
31 Mar 2026 //
GLOBENEWSWIRE
KDIGO Releases 2026 Draft Guideline on AKI and AKD Disease
31 Mar 2026 //
GLOBENEWSWIRE
Bioporto Announces The Annual Report For 2025
26 Mar 2026 //
GLOBENEWSWIRE
Notice convening the Annual General Meeting in BioPorto A/S
26 Mar 2026 //
GLOBENEWSWIRE
BioPorto Completes U.S. Adult NGAL Cutoff Study Analysis
18 Mar 2026 //
GLOBENEWSWIRE
Bioporto A/S Appoints Chief Financial Officer
09 Feb 2026 //
GLOBENEWSWIRE
BioPorto Unveils 2025 Financials, 2026 Guidance & Business Update
05 Feb 2026 //
GLOBENEWSWIRE
Changes to the Executive Management
11 Dec 2025 //
GLOBENEWSWIRE
Managers` Key Transactions
24 Nov 2025 //
GLOBENEWSWIRE
BioPorto A/S Secures DKK 43M in Funding Round
24 Nov 2025 //
GLOBENEWSWIRE
BioPorto Reports Q3 2025 Progress, NGAL Sales Growth
19 Nov 2025 //
GLOBENEWSWIRE
Bioporto Initiates Pre-Subscribed Private Placement
13 Nov 2025 //
GLOBENEWSWIRE
Bioporto A/S Completes Fully Subscribed Private Placement
13 Nov 2025 //
GLOBENEWSWIRE
Company Unveils `Forward` Strategic Direction & 2028
04 Nov 2025 //
GLOBENEWSWIRE
Key Financial Results Pre-Announced For Q3 2025
04 Nov 2025 //
GLOBENEWSWIRE
Progress Update On Bioporto`s Adult Clinical Study
04 Nov 2025 //
GLOBENEWSWIRE
BioPorto Sponsors Pediatric Critical Conferences With New Data
26 Sep 2025 //
GLOBENEWSWIRE
Webinar Highlights NGAL Biomarker in New Kidney Care Frontiers
11 Sep 2025 //
GLOBENEWSWIRE
Grant of Warrants
01 Sep 2025 //
GLOBENEWSWIRE
BioPorto Partners with Roche Diagnostics to Commercialize
28 Aug 2025 //
GLOBENEWSWIRE
BioPorto Q2 2025 Results: Strategic Progress, NGAL Sales Rise
15 Aug 2025 //
GLOBENEWSWIRE
BioPorto A/S Hosts Webcast on H1 2025 Results for Investors
29 Jul 2025 //
GLOBENEWSWIRE
BioPorto Attends Meeting on NGAL and Acute Kidney Injury Focus
28 Jul 2025 //
GLOBENEWSWIRE
ProNephro AKI (NGAL) commercialization for US diagnostics
27 Jun 2025 //
GLOBENEWSWIRE
Grant of Warrants
12 Jun 2025 //
GLOBENEWSWIRE
BioPorto A/S Appoints New CEO for Succession Planning
10 Jun 2025 //
GLOBENEWSWIRE
Q1 2025 Progress on Strategic Milestones, Revenue on Track
08 May 2025 //
GLOBENEWSWIRE
BioPorto A/S hosts Q1 2025 Earnings Webcast
28 Apr 2025 //
GLOBENEWSWIRE
Grant of Warrants
28 Apr 2025 //
GLOBENEWSWIRE
BioPorto A/S raises DKK 33.5 million in new capital round
25 Apr 2025 //
GLOBENEWSWIRE
Managers™ transactions
25 Apr 2025 //
GLOBENEWSWIRE
BioPorto completes oversubscribed offering, raises DKK 33.5 Million
25 Apr 2025 //
GLOBENEWSWIRE
25M new shares fully subscribed - DKK 33.5M gross proceeds to Bio
15 Apr 2025 //
GLOBENEWSWIRE
Private placement of 25,000,000 new shares fully subscribed, proceed
15 Apr 2025 //
GLOBENEWSWIRE
BioPorto Starts Placement for 25M New Shares At Market Price
14 Apr 2025 //
GLOBENEWSWIRE
Resolutions of the Annual General Meeting
11 Apr 2025 //
GLOBENEWSWIRE
Board candidates` updated bios for Annual General Meeting
01 Apr 2025 //
GLOBENEWSWIRE
BioPorto announces the Annual Report for 2024
20 Mar 2025 //
GLOBENEWSWIRE
Notice convening Annual General Meeting in BioPorto A/S
20 Mar 2025 //
GLOBENEWSWIRE
BioPorto Sets 2025 Guidance & 2026-2029 Aspirations
19 Mar 2025 //
GLOBENEWSWIRE
BioPorto Nominates Jens Due Olsen As Chair, Updates Board Candidates
04 Mar 2025 //
GLOBENEWSWIRE
BioPorto Enters Market Maker Deal With Danske, Names IR Head
27 Feb 2025 //
GLOBENEWSWIRE
BioPorto A/S appoints new interim Chairman of the Board
29 Jan 2025 //
GLOBENEWSWIRE
BioPorto Publishes Urinary NGAL Reference Ranges For Adults & Kids
23 Jan 2025 //
GLOBENEWSWIRE
Preliminary Financial Figures for the 2024 Fiscal Year
06 Jan 2025 //
GLOBENEWSWIRE
BioPorto Begins Process to Appoint New Chair of Board
16 Dec 2024 //
GLOBENEWSWIRE
BioPorto Announces Interim Q3 & Nine-Month Results & Updates
14 Nov 2024 //
GLOBENEWSWIRE
BioPorto A/S to Host Q3 2024 Earnings Webcast
12 Nov 2024 //
GLOBENEWSWIRE
BioPorto Showcases ProNephro AKI & NGAL Test at Conferences
08 Nov 2024 //
GLOBENEWSWIRE
Grant of Warrants
04 Nov 2024 //
GLOBENEWSWIRE
BioPorto Partners with Beckman Coulter for AKI NGAL Tests
28 Oct 2024 //
#N/A
BioPorto Presents FDA-Cleared ProNephro AKI at ASN Conference
23 Oct 2024 //
GLOBENEWSWIRE
BioPorto Serves Nine Of The Top Ten US Children’s Hospitals
22 Oct 2024 //
GLOBENEWSWIRE
BioPorto A/S Announces Changes to the US Commercial Organization
21 Oct 2024 //
GLOBENEWSWIRE
BioPorto Names PI And CRO For USA ICU Adult AKI Clinical Study
10 Oct 2024 //
GLOBENEWSWIRE
BioPorto Announces Q2 2024 Interim Results And Business Update
15 Aug 2024 //
GLOBENEWSWIRE
